IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RA |
|
The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. |
|
Aggrecanase- and matrix metalloproteinase-mediated aggrecan degradation is associated with different molecular characteristics of aggrecan and separated in time ex vivo |
|
Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development. |
|
Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities |
|
Biochemistry of collagens, laminins and elastin : structure, function and biomarkers |
|
Biological relevance of citrullinations: diagnostic, prognostic and therapeutic options |
|
Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients |
|
Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis. |
|
Bone phenotypes in rheumatology - there is more to bone than just bone |
|
Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis |
|
Characterization of an Ex vivo Femoral Head Model Assessed by Markers of Bone and Cartilage Turnover |
|
Characterization of the interleukin-17 effect on articular cartilage in a translational model: an explorative study |
|
The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease |
|
Citrullinated vimentin and biglycan protein fingerprints as candidate serological biomarkers for disease activity in systemic sclerosis: a pilot study |
|
Clinical and biochemical factors associated with risk of total joint replacement and radiographic progression in osteoarthritis: Data from two phase III clinical trials |
|
Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. |
|
The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? |
|
Dermal fibroblasts have different extracellular matrix profiles induced by TGF-β, PDGF and IL-6 in a model for skin fibrosis |
|
Diagnosis of Osteoarthritis by Cartilage Surface Smoothness Quantified Automatically from Knee MRI. |
|
The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? |
|
The distribution pattern of critically short telomeres in human osteoarthritic knees |
|
Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis |
|
Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnover. |
|
An Ex Vivo Tissue Culture Model of Cartilage Remodeling in Bovine Knee Explants |
|
Excessive matrix metalloprotease-mediated degradation of interstitial tissue (type I collagen) independently predicts short-term survival in an observational study of postmenopausal women diagnosed with cancer |
|
Expanding the citrullinome of synovial fibrinogen from rheumatoid arthritis patients |
|
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure |
|
Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls |
|
Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist. |
|
Glucocorticoids exert context-dependent effects on cells of the joint in vitro. |
|
GPDPLQ-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro |
|
Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment? |
|
The inhibitory effect of salmon calcitonin on tri-iodothyronine induction of early hypertrophy in articular cartilage |
|
Intercritical circulating levels of neo-epitopes reflecting matrixmetalloprotease-driven degradation as markers of gout and frequent gout attacks. |
|
Investigation of chondrocyte hypertrophy and cartilage calcification in a full-depth articular cartilage explants model |
|
Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes |
|
Matrix metalloproteinase-degraded type I collagen is associated with APOE/TOMM40 variants and preclinical dementia |
|
Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis |
|
Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease. |
|
Molecular serum and urine marker repertoire supporting clinical research on joint diseases |
|
Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes |
|
Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non-Small Cell Lung Cancer |
|
A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis |
|
Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? |
|
A Novel High Sensitivity Type II Collagen Blood-Based Biomarker, PRO-C2, for Assessment of Cartilage Formation |
|
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis |
|
Oral salmon calcitonin--pharmacology in osteoporosis |
|
Osteoarthritis phenotypes and novel therapeutic targets |
|
Potential diagnostic value of a type X collagen neo-epitope biomarker for knee osteoarthritis |
|
Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats |
|
Protein biomarkers associated with pain mechanisms in osteoarthritis. |
|
Recent advances in understanding the phenotypes of osteoarthritis |
|
Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study. |
|
The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover |
|
Rheumatoid arthritis: a case for personalized health care? |
|
Serological Assessment of the Quality of Wound Healing Processes in Crohn's Disease |
|
Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study |
|
Serum Biomarkers for Connective Tissue and Basement Membrane Remodeling are Associated with Vertebral Endplate Bone Marrow Lesions as Seen on MRI (Modic Changes) |
|
Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer |
|
Serum cartilage oligomeric matrix protein and development of radiographic and painful knee osteoarthritis. A community-based cohort of middle-aged women. |
|
Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers |
|
Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice? |
|
Sprifermin (rhFGF18) versus vehicle induces a biphasic process of extracellular matrix remodeling in human knee OA articular cartilage ex vivo |
|
Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis |
|
Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis |
|
Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis |
|
Tofacitinib and TPCA-1 exert chondroprotective effects on extracellular matrix turnover in bovine articular cartilage ex vivo |
|
Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat model |
|
Type I and III collagen turnover is increased in axial spondyloarthritis and psoriatic arthritis. Associations with disease activity and diagnostic capacity |
|
Type III, IV, and VI Collagens Turnover in Systemic Sclerosis - a Longitudinal Study |
|
Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease |
|
Unique insight into microenvironmental changes in colorectal cancer: Ex vivo assessment of matrix metalloprotease-mediated molecular changes in human colorectal tumor tissue and corresponding non-neoplastic adjacent tissue |
|
Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? |
|